Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-Α2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study
Sponsor: Diwakar Davar
This PHASE1 trial investigates Melanoma and is currently completed. Diwakar Davar leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Diwakar Davar
For direct contact, visit the study record on ClinicalTrials.gov .